{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:46:03Z","timestamp":1777614363882,"version":"3.51.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Drug Investigation"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s40261-012-0046-9","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T08:38:39Z","timestamp":1357202319000},"page":"71-91","source":"Crossref","is-referenced-by-count":41,"title":["Propiverine"],"prefix":"10.1007","volume":"33","author":[{"given":"Kate","family":"McKeage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,4]]},"reference":[{"issue":"2","key":"46_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167\u201378.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"46_CR2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","volume":"49","author":"C Chapple","year":"2006","unstructured":"Chapple C, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651\u20139.","journal-title":"Eur Urol"},{"issue":"2","key":"46_CR3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2008.02.017","volume":"54","author":"M Oelke","year":"2008","unstructured":"Oelke M, Baard J, Wijkstra H, et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54(2):419\u201326.","journal-title":"Eur Urol"},{"issue":"6","key":"46_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7150\/ijms.7.391","volume":"7","author":"WW Cheung","year":"2010","unstructured":"Cheung WW, Blank W, Borawski D, et al. Prevalence of overactive bladder, its under-diagnosis, and risk factors in a male urologic veterans population. Int J Med Sci. 2010;7(6):391\u20134.","journal-title":"Int J Med Sci"},{"issue":"6","key":"46_CR5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"4","key":"46_CR6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2005.04.026","volume":"48","author":"C Temml","year":"2005","unstructured":"Temml C, Heidler S, Ponholzer A, et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005;48(4):622\u20137.","journal-title":"Eur Urol"},{"issue":"1","key":"46_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.urology.2008.06.063","volume":"73","author":"JM Chung","year":"2009","unstructured":"Chung JM, Lee SD, Kang DI, et al. Prevalence and associated factors of overactive bladder in Korean children 5\u201313\u00a0years old: a nationwide multicentre study. Urology. 2009;73(1):63\u20139.","journal-title":"Urology"},{"issue":"1","key":"46_CR8","first-page":"36","volume":"13","author":"M Kajiwara","year":"2006","unstructured":"Kajiwara M, Inoue K, Kato M, et al. Nocturnal eneuresis and overactive bladder in children: an epidemiological study. Urology. 2006;13(1):36\u201341.","journal-title":"Urology"},{"issue":"1","key":"46_CR9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","volume":"56","author":"M St\u00f6hrer","year":"2009","unstructured":"St\u00f6hrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56(1):81\u20138.","journal-title":"Eur Urol"},{"issue":"4","key":"46_CR10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/01.ju.0000155709.37840.fe","volume":"173","author":"JT Wei","year":"2005","unstructured":"Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256\u201361.","journal-title":"J Urol"},{"key":"46_CR11","unstructured":"Lucas MG, Bosch JLHR, Cruz FR, et al. European Association of Urology. Guidelines on urinary incontinence (online). Available from URL: http:\/\/www.uroweb.org\/fileadmin\/guidelines\/2012 [Accessed 2012 Sep 6]."},{"issue":"2","key":"46_CR12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1442-2042.2008.02177.x","volume":"16","author":"O Yamaguchi","year":"2009","unstructured":"Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Int J Urol. 2009;16(2):126\u201342.","journal-title":"Int J Urol"},{"issue":"5","key":"46_CR13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s003450100223","volume":"19","author":"H Madersbacher","year":"2001","unstructured":"Madersbacher H, M\u00fcrtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001;19(5):324\u201335.","journal-title":"World J Urol"},{"issue":"5","key":"46_CR14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/sj.bjp.0706244","volume":"145","author":"M Wuest","year":"2005","unstructured":"Wuest M, Hecht J, Christ T, et al. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol. 2005;145(5):608\u201319.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"46_CR15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00210-006-0103-0","volume":"374","author":"M Wuest","year":"2006","unstructured":"Wuest M, Weiss A, Waelbroeck M, et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn-Schmied Arch Pharmacol. 2006;374(2):87\u201397.","journal-title":"Naunyn-Schmied Arch Pharmacol"},{"issue":"8","key":"46_CR16","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1124\/dmd.110.033233","volume":"38","author":"S Yamada","year":"2010","unstructured":"Yamada S, Ito Y, Taki Y, et al. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. Drug Metab Dispos. 2010;38(8):1314\u201321.","journal-title":"Drug Metab Dispos"},{"issue":"26","key":"46_CR17","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.lfs.2007.04.002","volume":"80","author":"S Uchida","year":"2007","unstructured":"Uchida S, Kurosawa S, Fujino Oki T, et al. Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci. 2007;80(26):2454\u201360.","journal-title":"Life Sci"},{"issue":"4","key":"46_CR18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00210-010-0493-x","volume":"381","author":"S Propping","year":"2010","unstructured":"Propping S, Braeter M, Grimm M-O, et al. Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. Naunyn-Schmied Arch Pharmacol. 2010;381(4):329\u201338.","journal-title":"Naunyn-Schmied Arch Pharmacol"},{"issue":"2","key":"46_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00424-007-0407-z","volume":"456","author":"M Wuest","year":"2008","unstructured":"Wuest M, Eichhorn B, Braeter M, et al. Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. Pflugers Arch. 2008;456(2):349\u201358.","journal-title":"Pflugers Arch"},{"issue":"2","key":"46_CR20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00345-011-0655-6","volume":"29","author":"M Wuest","year":"2011","unstructured":"Wuest M, Witte LP, Michel-Reher MB, et al. The muscarinic receptor antagonist propiverine exhibits \u03b11-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol. 2011;29(2):149\u201355.","journal-title":"World J Urol"},{"issue":"2","key":"46_CR21","first-page":"509","volume":"76","author":"HS Moon","year":"2010","unstructured":"Moon HS, Lee JW, ParK SY, et al. Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms. Urology. 2010;76(2):509. (e8\u201312).","journal-title":"Urology"},{"issue":"5","key":"46_CR22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.phrs.2007.02.002","volume":"55","author":"JR Scheepe","year":"2007","unstructured":"Scheepe JR, van den Hoek J, J\u00fcnemann KP, et al. A standardised mini pig model for in vivo investigations of anticholinergic effects on bladder function and salivation. Pharmacol Res. 2007;55(5):450\u20134.","journal-title":"Pharmacol Res"},{"issue":"6","key":"46_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00210-007-0231-1","volume":"376","author":"T Christ","year":"2008","unstructured":"Christ T, Wettwer E, Wuest M, et al. Electrophysiological profile of propiverine: relationship to cardiac risk. Naunyn-Schmied Arch Pharmacol. 2008;376(6):431\u201340.","journal-title":"Naunyn-Schmied Arch Pharmacol"},{"issue":"6","key":"46_CR24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5414\/CP201443","volume":"49","author":"F Donath","year":"2011","unstructured":"Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. Int J Clin Pharmacol Ther. 2011;49(6):353\u201365.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"46_CR25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF03191308","volume":"13","author":"KO Haustein","year":"1988","unstructured":"Haustein KO, Huller G. On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet. 1988;13(2):81\u201390.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"46_CR26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0091270008315314","volume":"48","author":"K May","year":"2008","unstructured":"May K, Westphal K, Giessmann T, et al. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms. J Clin Pharmacol. 2008;48(5):570\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"46_CR27","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00228-008-0528-0","volume":"64","author":"K May","year":"2008","unstructured":"May K, Giessmann T, Wegner D, et al. Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. Eur J Clin Pharmacol. 2008;64(11):1085\u201392.","journal-title":"Eur J Clin Pharmacol"},{"key":"46_CR28","unstructured":"Medicines Compendium UK. Detrunorm 15\u00a0mg tablets. Summary of product characteristics (online). Available from URL: http:\/\/www.medicines.org.uk\/emc\/medicine\/15252 . [Accessed 2012 August 6]."},{"key":"46_CR29","unstructured":"Medicines and Healthcare products Regulatory Agency. Public assessment report: Mictonorm XL 30\u00a0mg modified release capsules, Proprinorm XL 30\u00a0mg modified release capsules (online). Available from URL: http:\/\/www.mhra.gov.uk\/home\/groups\/I-unit1\/documents\/websiteresources\/con013950.pdf . [Accessed 2012 August 6]."},{"issue":"5","key":"46_CR30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0091270011401260","volume":"52","author":"W Siegmund","year":"2012","unstructured":"Siegmund W, Siegert J, Richter K, et al. Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine. J Clin Pharmacol. 2012;52(5):681\u201390.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"46_CR31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0031-1296223","volume":"61","author":"M Huang","year":"2011","unstructured":"Huang M, Tian Y, Zhang Z, et al. Determination of propiverine hydrochloride in human plasma by high performance liquid chromatography-tandem mass spectrometry: application to the pharmacokinetic study of a sustained release formulation. Arzneimittelforschung. 2011;61(9):494\u2013501.","journal-title":"Arzneimittelforschung"},{"issue":"12","key":"46_CR32","first-page":"1859","volume":"33","author":"D Tomalik-Scharte","year":"2005","unstructured":"Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33(12):1859\u201366.","journal-title":"Drug Metab Dispos."},{"issue":"5","key":"46_CR33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/11319990-000000000-00000","volume":"49","author":"W Siegmund","year":"2010","unstructured":"Siegmund W, Sillen U, Lackgren G, et al. Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10\u00a0years with symptoms of overactive bladder. Clin Pharmacokinet. 2010;49(5):335\u201342.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"46_CR34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jpurol.2011.07.014","volume":"8","author":"H Schulte-Baukloh","year":"2012","unstructured":"Schulte-Baukloh H, M\u00fcrtz G, Heine G, et al. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. J Pediatr Urol. 2012;8(4):386\u201392.","journal-title":"J Pediatr Urol"},{"issue":"3","key":"46_CR35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365599509180578","volume":"29","author":"D Mazur","year":"1995","unstructured":"Mazur D, Wehnert J, Dorschner W, et al. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. Scan J Urol Nephrol. 1995;29(3):289\u201394.","journal-title":"Scan J Urol Nephrol"},{"issue":"5","key":"46_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-2042.2011.02732.x","volume":"18","author":"M Gotoh","year":"2011","unstructured":"Gotoh M, Yokoyama O, Nishizawa O, et al. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int J Urol. 2011;18(5):365\u201373.","journal-title":"Int J Urol"},{"issue":"6","key":"46_CR37","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000020221","volume":"37","author":"W Dorschner","year":"2000","unstructured":"Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients: a double-blind, placebo-controlled clinical study. Eur Urol. 2000;37(6):702\u20138.","journal-title":"Eur Urol"},{"issue":"4","key":"46_CR38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000096338","volume":"77","author":"KP J\u00fcnemann","year":"2006","unstructured":"J\u00fcnemann KP, Hessdorfer E, Unamba-Oparah I, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006;77(4):334\u20139.","journal-title":"Urol Int"},{"issue":"11","key":"46_CR39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/j.1464-410X.2009.09050.x","volume":"105","author":"K-S Lee","year":"2010","unstructured":"Lee K-S, Lee HW, Choo M-S, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the \u2018propiverine study on overactive bladder including urgency data\u2019. BJU Int. 2010;105(11):1565\u201370.","journal-title":"BJU Int"},{"issue":"5","key":"46_CR40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1442-2042.2009.02286.x","volume":"16","author":"Y Homma","year":"2009","unstructured":"Homma Y, Yamaguchi O, Group IS. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2009;16(5):499\u2013506.","journal-title":"Int J Urol"},{"issue":"3","key":"46_CR41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-410X.2007.07031.x","volume":"100","author":"O Yamaguchi","year":"2007","unstructured":"Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100(3):579\u201387.","journal-title":"BJU Int"},{"key":"46_CR42","unstructured":"Leng J, Wan B, Du C, et al. Randomized clinical trial evaluating safety and efficacy of propiverine ER 30\u00a0mg and tolterodine ER 4\u00a0mg in the treatment of overactive bladder (abstract no. 338). International Continence Society Annual Meeting. Beijing; 2012 Oct 15\u201319."},{"issue":"6","key":"46_CR43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1442-2042.2006.01387.x","volume":"13","author":"P Abrams","year":"2006","unstructured":"Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol. 2006;13(6):692\u20138.","journal-title":"Int J Urol"},{"issue":"3","key":"46_CR44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2005.04.023","volume":"48","author":"K-P J\u00fcnemann","year":"2005","unstructured":"J\u00fcnemann K-P, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol. 2005;48(3):478\u201382.","journal-title":"Eur Urol"},{"issue":"6","key":"46_CR45","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1464-410x.1999.00251.x","volume":"84","author":"H Madersbacher","year":"1999","unstructured":"Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999;84(6):646\u201351.","journal-title":"BJU Int"},{"issue":"1","key":"46_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1757-5672.2010.00083.x","volume":"3","author":"N Wada","year":"2011","unstructured":"Wada N, Watanabe M, Kita M, et al. Efficacy and safety of propiverine and solifenacin for the treatment of female patients with overactive bladder: a crossover study. LUTS. 2011;3(1):36\u201342.","journal-title":"LUTS"},{"key":"46_CR47","doi-asserted-by":"crossref","unstructured":"Masumori N, Miyamoto S, Tsukamoto T, et al. The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents. Adv Urol. 2011. doi: 10.1155\/2011\/714978 .","DOI":"10.1155\/2011\/714978"},{"issue":"2","key":"46_CR48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","volume":"68","author":"Y Homma","year":"2006","unstructured":"Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome: overactive bladder symptom score. Urology. 2006;68(2):318\u201323.","journal-title":"Urology"},{"issue":"3","key":"46_CR49","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2008.04.062","volume":"55","author":"D Marschall-Kehrel","year":"2009","unstructured":"Marschall-Kehrel D, Feustel C, Persson de Geeter C, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol. 2009;55(3):729\u201336.","journal-title":"Eur Urol"},{"key":"46_CR50","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s00120-009-2086-1","volume":"48","author":"PL Kessler-Zumpe","year":"2009","unstructured":"Kessler-Zumpe PL, Murgas S, Neumann G, et al. Therapy of overactive bladder with propiverine ER. Results of a non-interventional study with propiverine retard formulation and comparison to clinical studies (in German). Urologe. 2009;48:1346\u201351.","journal-title":"Urologe"},{"key":"46_CR51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s001310050016","volume":"40","author":"S Alloussi","year":"2000","unstructured":"Alloussi S, Sch\u00f6nberger B, M\u00fcrtz G, et al. Treatment of the urge-syndrome with propiverine in therapeutic practice: tolerability and efficacy in 4390 patients (in German). Urologe B. 2000;40:367\u201373.","journal-title":"Urologe B"},{"key":"46_CR52","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.sc.3100750","volume":"37","author":"M St\u00f6hrer","year":"1999","unstructured":"St\u00f6hrer M, Madersbacher H, Richter R, et al. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial. Spinal Cord. 1999;37:196\u2013200.","journal-title":"Spinal Cord"},{"key":"46_CR53","first-page":"459","volume":"153","author":"H Takayasu","year":"1990","unstructured":"Takayasu H, Ueno A, Tsuchida S, et al. Clinical evaluation of propiverine hydrochloride (P4) against pollakisuria and urinary incontinence: a multicenter, placebo-controlled double-blind study (in Japanese). Prog Med. 1990;153:459\u201371.","journal-title":"Prog Med"},{"key":"46_CR54","unstructured":"St\u00f6hrer M, Murtz G, Kramer G, et al. Efficacy and tolerability of propiverine hydrochloride extended release compared to immediate release in patients with neurogenic detrusor overactivity (abstract no. 448). International Continence Society Annual Meeting. San Francisco; 2009 Sep 29 \u20132009 Oct 3."},{"issue":"1","key":"46_CR55","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.eururo.2006.03.016","volume":"51","author":"M St\u00f6hrer","year":"2007","unstructured":"St\u00f6hrer M, M\u00fcrtz G, Kramer G, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity: results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007;51(1):235\u201342.","journal-title":"Eur Urol"},{"issue":"4","key":"46_CR56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4111\/kju.2011.52.4.274","volume":"52","author":"JH Bae","year":"2011","unstructured":"Bae JH, Kim SO, Yoo ES, et al. Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms\/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol. 2011;52(4):274\u20138.","journal-title":"Korean J Urol"},{"issue":"4 Pt 1","key":"46_CR57","first-page":"1334","volume":"174","author":"KS Lee","year":"2005","unstructured":"Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174(4 Pt 1):1334\u20138.","journal-title":"J Urol"},{"key":"46_CR58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1757-5672.2010.00081.x","volume":"3","author":"O Nishizawa","year":"2011","unstructured":"Nishizawa O, Yamaguchi O, Takeda M, et al. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. LUTS. 2011;3:29\u201335.","journal-title":"LUTS"},{"key":"46_CR59","first-page":"525","volume":"12","author":"H Saito","year":"1999","unstructured":"Saito H, Yamada T, Oshima H, et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and\/or urinary incontinence (in Japanese). Jpn J Urol Surg. 1999;12:525\u201336.","journal-title":"Jpn J Urol Surg"},{"issue":"11","key":"46_CR60","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4111\/kju.2009.50.11.1078","volume":"50","author":"KI Seo","year":"2009","unstructured":"Seo KI, Hong SZ, Lee JB. The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms (in Korean). Korean J Urol. 2009;50(11):1078\u201382.","journal-title":"Korean J Urol"},{"issue":"4","key":"46_CR61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/00365590902836740","volume":"43","author":"T Yokoyama","year":"2009","unstructured":"Yokoyama T, Uematsu K, Watanabe T, et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol. 2009;43(4):307\u201314.","journal-title":"Scand J Urol Nephrol"},{"key":"46_CR62","doi-asserted-by":"crossref","unstructured":"Matsukawa Y, Hattori R, Mazima T, et al. Is combination therapy with an anticholinergic agent and an alpha1-adrenoceptor antagonist useful as first-line treatment in patients with benign prostatic hyperplasia complicated by overactive bladder? A randomized, prospective, comparative study using a urodynamic study (abstract no. 753). 27th Congress of the European Association of Urology. Paris; 2012 Feb 24\u201328.","DOI":"10.1016\/S1569-9056(12)60750-7"},{"key":"46_CR63","first-page":"71","volume":"57","author":"N Kamimura","year":"2011","unstructured":"Kamimura N, Hatakeyama S, Kudo S, et al. Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy (in Japanese). Hinyokika Kiyo. 2011;57:71\u20136.","journal-title":"Hinyokika Kiyo"},{"issue":"2","key":"46_CR64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00345-011-0654-7","volume":"29","author":"M Oelke","year":"2011","unstructured":"Oelke M, Murgas S, Baumann I, et al. Efficacy of propiverine ER with or without alpha-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. World J Urol. 2011;29(2):217\u201323.","journal-title":"World J Urol"},{"issue":"4","key":"46_CR65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4111\/kju.2012.53.4.275","volume":"53","author":"WJ Kim","year":"2012","unstructured":"Kim WJ, Lee D-G, Lee SW, et al. Efficacy and safety of propiverine in children with overactive bladder. Korean J Urol. 2012;53(4):275\u20139.","journal-title":"Korean J Urol"},{"issue":"4","key":"46_CR66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1464-410X.2009.09129.x","volume":"106","author":"S Alloussi","year":"2010","unstructured":"Alloussi S, M\u00fcrtz G, Braun R, et al. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study. BJU Int. 2010;106(4):550\u20136.","journal-title":"BJU Int"},{"issue":"2","key":"46_CR67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1464-410X.2006.05953.x","volume":"97","author":"H Schulte-Baukloh","year":"2006","unstructured":"Schulte-Baukloh H, M\u00fcrtz G, Henne T, et al. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. BJU Int. 2006;97(2):355\u20138.","journal-title":"BJU Int"},{"issue":"6","key":"46_CR68","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.eururo.2006.02.026","volume":"49","author":"U Grigoleit","year":"2006","unstructured":"Grigoleit U, M\u00fcrtz G, Laschke S, et al. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity: a retrospective study. Eur Urol. 2006;49(6):1114\u201320.","journal-title":"Eur Urol"},{"issue":"6","key":"46_CR69","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1464-410X.2008.08093.x","volume":"103","author":"H Madersbacher","year":"2009","unstructured":"Madersbacher H, M\u00fcrtz G, Alloussi S, et al. Propiverine vs. oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int. 2009;103(6):776\u201381.","journal-title":"BJU Int"},{"key":"46_CR70","unstructured":"Apogepha. Mictonetten\u00ae 5\u00a0mg coated tablets. Product information leaflet (online). Available from URL: http:\/\/www.apogepha.de\/de\/gesundheit\/mictonetten.html . [Accessed 2012 Nov 19]."},{"key":"46_CR71","first-page":"687","volume":"44","author":"K Noguchi","year":"1998","unstructured":"Noguchi K, Masuda M, Noguchi S, et al. Longterm administration study of propiverine hydrochloride (BUP-4\u00ae tablets) in pollakiuria and urinary incontinence (in Japanese). Hinyokika Kiyo. 1998;44:687\u201393.","journal-title":"Hinyokika Kiyo"},{"key":"46_CR72","unstructured":"Medicines and Healthcare products Regulatory Agency. Public assessment report: Mictonorm XL 45\u00a0mg modified release capsules (propiverine hydrochloride) (online). Available from URL: http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con143796.pdf . [Accessed 2012 August 6]."},{"key":"46_CR73","unstructured":"Medicines Compendium UK. Detrunorm XL 30\u00a0mg modified release capsules. Summary of product characteristics (online). Available from URL: http:\/\/www.medicines.org.uk\/emc\/medicine\/18501 . [Accessed 2012 Nov 14]."},{"issue":"4","key":"46_CR74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MOU.0b013e32833aa185","volume":"20","author":"A Schr\u00f6der","year":"2010","unstructured":"Schr\u00f6der A, Th\u00fcroff JW. New strategies for medical management of overactive bladder in children. Curr Opin Urol. 2010;20(4):313\u20137.","journal-title":"Curr Opin Urol"},{"key":"46_CR75","unstructured":"Oelke M, Bachmann A, Descazeaud A, et al. European association of urology. Guidelines of the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Available from URL: http:\/\/www.uroweb.org\/gls\/pdf\/ . [Accessed 2012 Sep 6]."},{"issue":"3","key":"46_CR76","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543\u201362.","journal-title":"Eur Urol"},{"issue":"3","key":"46_CR77","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000339600","volume":"89","author":"AD Asimakopoulos","year":"2012","unstructured":"Asimakopoulos AD, Cerruto MA, Del Popolo G, et al. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. Urol Int. 2012;89(3):259\u201369.","journal-title":"Urol Int"},{"issue":"1","key":"46_CR78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1464-410X.2006.06574.x","volume":"99","author":"BT Blake-James","year":"2006","unstructured":"Blake-James BT, Rashidian A, Ikeda Y, et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int. 2006;99(1):85\u201396.","journal-title":"BJU Int"},{"issue":"7","key":"46_CR79","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1532-5415.2011.03473.x","volume":"59","author":"A Paquette","year":"2011","unstructured":"Paquette A, Gou P, Tannenbaum C, et al. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59(7):1332\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"46_CR80","unstructured":"Uchiyama T, Sakakibara R, Liu Z, et al. The effects of anticholinergic drugs for overactive bladder on cognitive impairment, mental dysfunction and motor dysfunction in patients with neurological disease (abstract no. 245). International Continence Society Annual Meeting. Montreal; 2005 Aug 28\u20132005 Sep 2."},{"issue":"8","key":"46_CR81","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1532-5415.2009.02369.x","volume":"57","author":"R Sakakibara","year":"2009","unstructured":"Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist (letter). J Am Geriatr Soc. 2009;57(8):1515\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"46_CR82","unstructured":"Kluge A, Vohs K, Siegert J, et al. Effect of propiverine on psychomotor performance (abstract no. P319). International Continence Society Annual Meeting. Athens; 1996 Aug 27\u201330."},{"issue":"11 Suppl.","key":"46_CR83","first-page":"506","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl.):506\u201314.","journal-title":"Am J Manag Care"},{"issue":"4","key":"46_CR84","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1464-410X.2009.09160.x","volume":"106","author":"L Cardozo","year":"2000","unstructured":"Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs. fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2000;106(4):506\u201314.","journal-title":"BJU Int"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0046-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0046-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0046-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T03:45:10Z","timestamp":1644032710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0046-9"}},"subtitle":["A Review of its Use in the Treatment of Adults and Children with Overactive Bladder Associated with Idiopathic or Neurogenic Detrusor Overactivity, and in Men with Lower Urinary Tract Symptoms"],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0046-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}